報價延遲最少15分鐘:2024/05/16 18:31 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9597 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.67/-0.21
|
|
企業價值
221.12M
|
| 資產負債 |
|
每股賬面淨值
0.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 18:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditionsresulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |